Bolt Biotherapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M |
| Operating income | -$36.1M | -$73.0M | -$76.2M | -$90.3M | -$92.8M |
| Operating expenses | $43.8M | $80.7M | $84.1M | $96.0M | $94.0M |
| Cash from operations | -$39.9M | -$61.3M | -$69.5M | -$76.5M | -$57.1M |
| Capital expenditure | $72,000 | $41,000 | $206,000 | $2.0M | $2.3M |
| Free cash flow | -$39.9M | -$61.3M | -$69.7M | -$78.5M | -$59.4M |
| Impairments | $0 | $1.5M | $0 | $0 | $0 |
| Total assets | $56.7M | $99.6M | $159.8M | $227.8M | $307.7M |
| Total liabilities | $30.2M | $42.4M | $47.0M | $56.3M | $57.6M |
Shares outstanding 1.9M · Free float 15.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.